nach oben

PharmacoEconomics

Erschienen in:

01.12.2014 | Systematic Review

The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review

verfasst von: Erika Wissinger, Ingolf Griebsch, Juliane Lungershausen, Michael Byrnes, Karin Travers, Chris L. Pashos

Erschienen in: PharmacoEconomics | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Head and neck cancer (HNC) and its treatment can affect communication, nutrition, and physical appearance, and the global impact of this disease on patients’ quality of life may be substantial.

Objective

The aim of this systematic literature review was to describe the impact of HNC and its treatment on the physical, emotional, and social well-being of patients over time, by examining longitudinal studies of patient-reported outcomes (PRO) evaluating these domains.

Methods

Databases (MEDLINE and Embase) were searched to identify studies published in English between January 2004 and January 2014 analyzing the humanistic aspects of HNC in adult patients. Additional relevant publications were identified through manual searches of abstracts from recent conference proceedings.

Results

Of 1,566 studies initially identified, 130 met the inclusion criteria and were evaluated in the assessment. Investigations using a variety of PRO instruments in heterogeneous patient populations consistently reported that PRO scores decrease significantly from diagnosis through the treatment period, but generally recover to baseline in the first year post-treatment. This trend was observed for many functional domains, although some side effects, such as xerostomia, persisted well beyond 1 year. In addition, considerable evidence exists that baseline PRO scores can predict clinical endpoints such as overall and progression-free survival.

Conclusions

Many aspects of HNC, both disease and treatment specific, profoundly affect patients’ quality of life. Improved knowledge of these effects on PRO may allow for more informed treatment decisions and can help physicians to better prepare patients for changes they may experience during therapy. Furthermore, the predictive value of baseline PRO data may enable healthcare providers to identify at-risk patients in need of more intensive intervention.

Nur mit Berechtigung zugänglich

De Boer MF, McCormick LK, Pruyn JF, et al. Physical and psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol Head Neck Surg. 1999;120(3):427–36.PubMed

Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19–28.PubMed

Ojo B, Genden EM, Teng MS, et al. A systematic review of head and neck cancer quality of life assessment instruments. Oral Oncol. 2012;48(10):923–37.PubMedCentralPubMed

Dropkin MJ. Coping with disfigurement and dysfunction after head and neck cancer surgery: a conceptual framework. Semin Oncol Nurs. 1989;5(3):213–9.PubMed

Meyer F, Fortin A, Gelinas M, et al. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol. 2009;27(18):2970–6.PubMed

Curado MP, Boyle P. Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Curr Opin Oncol. 2013;25(3):229–34.PubMed

Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.

Ronis DL, Duffy SA, Fowler KE, et al. Changes in quality of life over 1 year in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134(3):241–8.PubMed

Abendstein H, Nordgren M, Boysen M, et al. Quality of life and head and neck cancer: a 5 year prospective study. Laryngoscope. 2005;115(12):2183–92.PubMed

10.

Ackerstaff AH, Balm AJ, Rasch CR, et al. First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial. Head Neck. 2009;31(1):77–84.PubMed

11.

Ahlberg A, Engstrom T, Nikolaidis P, et al. Early self-care rehabilitation of head and neck cancer patients. Acta Otolaryngol. 2011;131(5):552–61.PubMedCentralPubMed

12.

Al-Mamgani A, Levendag PC, Van Rooij P, et al. Intensity-modulated radiotherapy followed by a brachytherapy boost for oropharyngeal cancer. Head Neck. 2013;35(12):1689–97.PubMed

13.

Al-Mamgani A, Van Rooij P, Meeuwis CA, et al. Unilateral neck irradiation for well-lateralized oropharyngeal cancer: excellent outcome, low toxicity profile, and good quality of life scores. Int J Radiat Oncol Biol Phys. 2012;84(3):S22.

14.

Al-Mamgani A, van Rooij P, Tans L, et al. A prospective evaluation of patient-reported quality-of-life after (chemo)radiation for oropharyngeal cancer: which patients are at risk of significant quality-of-life deterioration? Radiother Oncol. 2013;106(3):359–63.PubMed

15.

Bairati I, Meyer F, Gelinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005;23(24):5805–13.PubMed

16.

Beetz I, Schilstra C, van der Schaaf A, et al. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors. Radiother Oncol. 2012;105(1):101–6.PubMed

17.

Beetz I, Schilstra C, Visink A, et al. Role of minor salivary glands in developing patient-rated xerostomia and sticky saliva during day and night. Radiother Oncol. 2013;109(2):311–6.PubMed

18.

Beisland E, Aarstad AK, Osthus AA, et al. Stability of distress and health-related quality of life as well as relation to neuroticism, coping and TNM stage in head and neck cancer patients during follow-up. Acta Otolaryngol. 2013;133(2):209–17.PubMed

19.

Blakaj D, Godoy-Scripes P, Skinner WK, et al. Prospective analysis of qol in patients undergoing concurrent chemotherapy and radiation therapy for locally advanced head and neck cancer. J Clin Oncol. 2012;30(suppl; abstract 16058).

20.

Bottomley A, Tridello G, Coens C, et al. An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC head and neck and the EORTC radiation oncology group. Cancer. 2014;120(3):390–8.

21.

Boyd NH, Funk GF, Bayon R, et al. Abstract No. S213: health related quality of life in long term head and neck cancer survivors: comparison of pre-treatment, 1 year post-treatment, and 5 years post-treatment SF-36 scores. 8th International Conference on Head and Neck Cancer. 2012; Toronto, Canada.

22.

Brown JS, Rogers SN, Lowe D. A comparison of tongue and soft palate squamous cell carcinoma treated by primary surgery in terms of survival and quality of life outcomes. Int J Oral Maxillofac Surg. 2006;35(3):208–14.PubMed

23.

Burke W, Schmid K, Lydiatt W. Prevention of depression using escitalopram in patients undergoing treatment for head and neck cancer. Am J Geriatr Psychiatry. 2013;21(3):S133.

24.

Burke W, Schmid K, Sharma A, et al. Preventing depression in patients initiating treatment for head and neck cancer. Psycho-Oncol. 2013;22:32.

25.

Chang J, Huang S, Kang C, et al. The health-related quality of life for hypopharyngeal and laryngeal cancer patients receiving organ preservation treatment. Int J Radiat Oncol Biol Phys. 2012;84(3):S496.

26.

Chen AM, Farwell DG, Luu Q, et al. Intensity-modulated radiotherapy is associated with improved global quality of life among long-term survivors of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):170–5.PubMed

27.

Corry J, Poon W, McPhee N, et al. Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation. Head Neck. 2009;31(7):867–76.PubMed

28.

Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007;25(16):2191–7.PubMed

29.

D’Cruz AK, Robinson MH, Biel MA. mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients. Head Neck. 2004;26(3):232–40.PubMed

30.

de Leeuw J, Prins JB, Teerenstra S, et al. Nurse-led follow-up care for head and neck cancer patients: a quasi-experimental prospective trial. Support Care Cancer. 2013;21(2):537–47.PubMed

31.

Derks W, De Leeuw R, Winnubst J, et al. Elderly patients with head and neck cancer: physical, social and psychological aspects after 1 year. Acta Otolaryngol. 2004;124(4):509–14.PubMed

32.

Derks W, de Leeuw RJ, Hordijk GJ, et al. Quality of life in elderly patients with head and neck cancer one year after diagnosis. Head Neck. 2004;26(12):1045–52.PubMed

33.

Derks W, Leeuw JR, Hordijk GJ, et al. Differences in coping style and locus of control between older and younger patients with head and neck cancer. Clin Otolaryngol. 2005;30(2):186–92.PubMed

34.

Donatelli-Lassig AA, Duffy SA, Fowler KE, et al. The effect of neck dissection on quality of life after chemoradiation. Otolaryngol Head Neck Surg. 2008;139(4):511–8.PubMed

35.

Duffy S, Terrell J, Light E, et al. Abstract No. S235: predictors of pain among head and neck cancer patients. 8th International Conference on Head and Neck Cancer. 2012; Toronto, Canada.

36.

Duffy SA, Ronis DL, Valenstein M, et al. A tailored smoking, alcohol, and depression intervention for head and neck cancer patients. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2203–8.PubMed

37.

Duncan GG, Epstein JB, Tu D, et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005;27(5):421–8.PubMed

38.

El-Deiry MW, Futran ND, McDowell JA, et al. Influences and predictors of long-term quality of life in head and neck cancer survivors. Arch Otolaryngol Head Neck Surg. 2009;135(4):380–4.PubMed

39.

Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113(10):2704–13.PubMed

40.

Epstein JB, Wilkie DJ, Fischer DJ, et al. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol. 2009;1:26.PubMedCentralPubMed

41.

Fang F, Chien C. Abstract No. P611: prognostic value of quality of life during follow-up on survival for patients with nasopharyngeal carcinoma after treatment. 8th International Conference on Head and Neck Cancer. 2012; Toronto, Canada.

42.

Fang FM, Liu YT, Tang Y, et al. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer. 2004;100(2):425–32.PubMed

43.

Finizia CA. Incidence of trismus in head and neck cancer. Otolaryngol Head Neck Surg. 2012;147:P137–8.

44.

Funk GF, Karnell LH, Christensen AJ. Long-term health-related quality of life in survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg. 2012;138(2):123–33.PubMed

45.

Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy—a randomized controlled trial. Support Care Cancer. 2013;21(5):1421–8.PubMed

46.

Ghazali N, Cadwallader E, Lowe D, et al. Fear of recurrence among head and neck cancer survivors: longitudinal trends. Psycho-Oncol. 2013;22(4):807–13.

47.

Goldstein DP, Hynds Karnell L, Christensen AJ, et al. Health-related quality of life profiles based on survivorship status for head and neck cancer patients. Head Neck. 2007;29(3):221–9.PubMed

48.

Gupta S, Khan H, Barik S, et al. Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer. Drug Discov Ther. 2013;7(1):36–42.PubMed

49.

Gupta S, Khan H, Barik S, et al. Efficacy of concurrent chemoradiotherapy with capecitabine and cisplatin in the management of locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer. 2013;49:S2.

50.

Gupta S, Singh PK, Bhatt ML, et al. Clinical benefits of two different dosing schedules of recombinant human erythropoietin in anemic patients with advanced head and neck cancer. Biosci Trends. 2010;4(5):267–72.PubMed

51.

Hodges LJ, Humphris GM. Fear of recurrence and psychological distress in head and neck cancer patients and their carers. Psycho-Oncol. 2009;18(8):841–8.

52.

Howren MB, Christensen AJ, Hynds Karnell L, et al. Influence of pretreatment social support on health-related quality of life in head and neck cancer survivors: results from a prospective study. Head Neck. 2013;35(6):779–87.PubMed

53.

Howren MB, Christensen AJ, Karnell LH, et al. Health-related quality of life in head and neck cancer survivors: impact of pretreatment depressive symptoms. Health Psychol. 2010;29(1):65–71.PubMed

54.

Jellema AP, Slotman BJ, Doornaert P, et al. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69(3):751–60.PubMed

55.

Jha N, Seikaly H, Harris J, et al. Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia. Head Neck. 2009;31(2):234–43.PubMed

56.

Jolly S, Peterson LA, Rozek LS, et al. Longitudinal changes in physical activity of head and neck squamous cell carcinoma patients. J Clin Oncol. 2013;31(suppl; abstr 9607).

57.

Karvonen-Gutierrez CA, Ronis DL, Fowler KE, et al. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol. 2008;26(16):2754–60.PubMed

58.

Kelly C, Paleri V, Downs C, et al. Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg. 2007;136(1):108–11.PubMed

59.

Kerr P, Taylor SM, Rigby M, et al. Oncologic and voice outcomes after treatment of early glottic cancer: transoral laser microsurgery versus radiotherapy. Otolaryngol Head Neck Surg. 2012;41(6):381–8.

60.

Lai YH, Cheng YJ, Wang CP, et al. Changes quality of life in newly diagnosed oral cavity cancer patients—Overall trajectory, related factors and sub-patterns of QOL during the first 12-month of diagnosis. Oral Oncol. 2013;49:S31–2.

61.

Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26(22):3770–6.PubMed

62.

Langius JA, Doornaert P, Spreeuwenberg MD, et al. Radiotherapy on the neck nodes predicts severe weight loss in patients with early stage laryngeal cancer. Radiother Oncol. 2010;97(1):80–5.PubMed

63.

Langius JA, van Dijk AM, Doornaert P, et al. More than 10 % weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life. Nutr Cancer. 2013;65(1):76–83.PubMed

64.

Lango M, Fang C, Schwartz S, et al. Abstract No. P594: patient-reported pain and dysphagia, not functional assessment of swallowing, predicts survival in untreated head and neck patients. 8th International Conference on Head and Neck Cancer. 2012; Toronto, Canada.

65.

Lango MN, Egleston B, Fang C, et al. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer. 2014;120(6):840–7.

66.

Laverick S, Lowe D, Brown JS, et al. The impact of neck dissection on health-related quality of life. Arch Otolaryngol Head Neck Surg. 2004;130(2):149–54.PubMed

67.

Lee R, Slevin N, Musgrove B, et al. Prediction of post-treatment trismus in head and neck cancer patients. Br J Oral Maxillofac Surg. 2012;50(4):328–32.PubMed

68.

Lydiatt W, Bessette D, Schmid K, et al. Abstract No. S032: prevention of depression using escitalopram in patients undergoing treatment for head and neck cancer. American Head and Neck Society Annual Meeting. 2013; Orlando, FL, USA.

69.

Lydiatt WM, Bessette D, Schmid KK, et al. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol Head Neck Surg. 2013;139(7):678–86.PubMed

70.

Manas A, Palacios A, Contreras J, et al. Incidence of oral mucositis, its treatment and pain management in patients receiving cancer treatment at Radiation Oncology Departments in Spanish hospitals (MUCODOL Study). Clin Transl Oncol. 2009;11(10):669–76.PubMed

71.

Maxwell JH, Mehta V, Wang H, et al. Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality. Laryngoscope. 2014;127(7):1592–7.

72.

Mehanna HM, Morton RP. Deterioration in quality-of-life of late (10-year) survivors of head and neck cancer. Clin Otolaryngol. 2006;31(3):204–11.PubMed

73.

Mehanna HM, Morton RP. Does quality of life predict long-term survival in patients with head and neck cancer? Arch Otolaryngol Head Neck Surg. 2006;132(1):27–31.PubMed

74.

Mehta V, Kubicek GJ, Jaber JJ, et al. Abstract No. S314: functional outcomes in head and neck squamous cell carcinoma after treatment: the effect of P16 status and treatment modality on quality of life. 8th International Conference on Head and Neck Cancer. 2012; Toronto, Canada.

75.

Mesia R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010;21(10):1967–73.PubMedCentralPubMed

76.

Milecki P, Zmijewska-Tomczak M. Comparison of quality of life (QOL) in patients with locally advanced head-and-neck cancer prior and 1 year after the completion of radiation therapy. Int J Rad Oncol Biol Phys. 2012;84(3):S649.

77.

Milecki P, Zmijewska-Tomczak M. What are the factors that negatively affect patients’ quality of life (QoL) during the course of radiotherapy for head and neck cancer? Eur Arch Otorhinolaryngol. 2012;269(4):1339.

78.

Milecki P, Zmijewska-Tomczak MZT, Rucinska AR, et al. Which factors affect the patients quality of life during the course of radiotherapy for head and neck cancer? Radiother Oncol. 2012;103:S284.

79.

Millsopp L, Brandom L, Humphris G, et al. Facial appearance after operations for oral and oropharyngeal cancer: a comparison of casenotes and patient-completed questionnaire. Br J Oral Maxillofac Surg. 2006;44(5):358–63.PubMed

80.

Moubayed SP, Sampalis JS, Gologan O, et al. Predicting quality of life in oral and oropharyngeal cancer. Otolaryngol Head Neck Surg. 2012;147:P64.

81.

Murali-Ganesh R, Bece A, Oates J, et al. Effect of age on quality of life changes during head and neck cancer treatment. Asia Pac J Clin Oncol. 2013;9:89.

82.

Neilson KA, Pollard AC, Boonzaier AM, et al. Psychological distress (depression and anxiety) in people with head and neck cancers. Med J Aust. 2010;193(5 Suppl):S48–51.PubMed

83.

Nibu K, Ebihara Y, Ebihara M, et al. Quality of life after neck dissection: a multicenter longitudinal study by the Japanese Clinical Study Group on Standardization of Treatment for Lymph Node Metastasis of Head and Neck Cancer. Int J Clin Oncol. 2010;15(1):33–8.PubMed

84.

Nourissat A, Bairati I, Fortin A, et al. Factors associated with weight loss during radiotherapy in patients with stage I or II head and neck cancer. Support Care Cancer. 2012;20(3):591–9.PubMed

85.

Nourissat A, Bairati I, Samson E, et al. Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer. Cancer. 2010;116(9):2275–83.PubMed

86.

Oates J, Clark JR, Read J, et al. Integration of prospective quality of life and nutritional assessment as routine components of multidisciplinary care of patients with head and neck cancer. ANZ J Surg. 2008;78(1–2):34–41.PubMed

87.

Olthoff A, Steuer-Vogt MK, Licht K, et al. Quality of life after treatment for laryngeal carcinomas. ORL J Otorhinolaryngol Relat Spec. 2006;68(5):253–8.PubMed

88.

O’Neill M, Heron DE, Flickinger JC, et al. Posttreatment quality-of-life assessment in patients with head and neck cancer treated with intensity-modulated radiation therapy. Am J Clin Oncol. 2011;34(5):478–82.PubMed

89.

Osthus A, Aarstad AKH, Olofsson J, et al. Abstract No. P610: pre-treatment health related quality of life scores predict survival in a prospective cohort of head and neck squamous cell carcinoma patients. 8th International Conference on Head and Neck Cancer. 2012; Toronto, Canada.

90.

Osthus AA, Aarstad AK, Olofsson J, et al. Head and neck specific Health Related Quality of Life scores predict subsequent survival in successfully treated head and neck cancer patients: a prospective cohort study. Oral Oncol. 2011;47(10):974–9.PubMed

91.

Osthus AA, Aarstad AK, Olofsson J, et al. Health-related quality of life scores in long-term head and neck cancer survivors predict subsequent survival: a prospective cohort study. Clin Otolaryngol. 2011;36(4):361–8.PubMed

92.

Osthus AA, Aarstad AK, Olofsson J, et al. Prediction of survival by pretreatment health-related quality-of-life scores in a prospective cohort of patients with head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013;139(1):14–20.PubMed

93.

Patterson JM, McColl E, Carding PN, et al. Swallowing in the first year after chemoradiotherapy for head and neck cancer: clinician-and patient-reported outcomes. Head Neck. 2014;36(3):352–8.

94.

Potash AE, Karnell LH, Christensen AJ, et al. Continued alcohol use in patients with head and neck cancer. Head Neck. 2010;32(7):905–12.PubMed

95.

Quinten C, Martinelli F, Coens C, et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120(2):302–11.

96.

Quinten C, Zikos E, Sprangers M, et al. An international study of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different cancer sites. J Clin Oncol. 2012;30(suppl; abstr 6002).

97.

Ringash J, Fisher R, Peters LJ, et al. Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: results of TROG 02.02. J Clin Oncol. 2012;30(suppl; abstr 5571).

98.

Ringash J, Warde P, Lockwood G, et al. Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys. 2005;61(5):1403–7.PubMed

99.

Rischin D, Peters LJ, O’Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28(18):2989–95.PubMed

100.

Rishi A, Ghoshal S, Sharma SC. Comparison of concomitant boost radiation therapy and concurrent chemoradiation in locally advanced oropharyngeal cancers: a phase 3 randomized trial from a single institute in India. Int J Radiat Oncol Biol Phys. 2013;87(2):S57.

101.

Rishi A, Ghoshal S, Verma R, et al. Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: a phase III randomised trial. Radiother Oncol. 2013;107(3):317–24.PubMed

102.

Rogers S, Kenyon P, Lowe D, et al. The relation between health-related quality of life, past medical history, and American Society of Anesthesiologists’ ASA grade in patients having primary operations for oral and oropharyngeal cancer. Br J Oral Maxillofac Surg. 2005;43(2):134–43.PubMed

103.

Rogers SN, Devine J, Lowe D, et al. Longitudinal health-related quality of life after mandibular resection for oral cancer: a comparison between rim and segment. Head Neck. 2004;26(1):54–62.PubMed

104.

Ryu JK, Swann S, LeVeque F, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys. 2007;67(3):643–50.PubMed

105.

Scarantino C, LeVeque F, Swann RS, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol. 2006;4(5):252–8.PubMed

106.

Scharloo M, Baatenburg de Jong RJ, Langeveld TP, et al. Illness cognitions in head and neck squamous cell carcinoma: predicting quality of life outcome. Support Care Cancer. 2010;18(9):1137–45.PubMedCentralPubMed

107.

Scharpf J, Karnell LH, Christensen AJ, et al. The role of pain in head and neck cancer recurrence and survivorship. Arch Otolaryngol Head Neck Surg. 2009;135(8):789–94.PubMed

108.

Schultze-Mosgau S, Mueller CK. Abstract No. P627: a prospective study on donor site morbidity and satisfaction in oral cancer patients undergoing ablative surgery and primary reconstruction employing microvascular free flaps. 8th International Conference on Head and Neck Cancer. 2012; Toronto, Canada.

109.

Schultze-Mosgau S, Mueller CK. Abstract No. P636: influence of multimodal treatment on the health related quality of life in oral cancer patients—a prospective study. 8th International Conference on Head and Neck Cancer. 2012; Toronto, Canada.

110.

Shuman AG, Duffy SA, Ronis DL, et al. Predictors of poor sleep quality among head and neck cancer patients. Laryngoscope. 2010;120(6):1166–72.PubMedCentralPubMed

111.

Shuman AG, Terrell JE, Light E, et al. Predictors of pain among patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2012;138(12):1147–54.PubMedCentralPubMed

112.

Siddiqui F, Pajak TF, Watkins-Bruner D, et al. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys. 2008;70(2):353–60.PubMed

113.

Silander E, Jacobsson I, Berteus-Forslund H, et al. Energy intake and sources of nutritional support in patients with head and neck cancer—a randomised longitudinal study. Eur J Clin Nutr. 2013;67(1):47–52.PubMed

114.

Silander E, Nyman J, Bove M, et al. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck. 2012;34(1):1–9.PubMed

115.

Silander E, Nyman J, Hammerlid E. An exploration of factors predicting malnutrition in patients with advanced head and neck cancer. Laryngoscope. 2013;123(10):2428–34.PubMed

116.

Simcock R, Fallowfield L, Monson K, et al. ARIX: a randomized trial of acupuncture versus oral care sessions in patients with chronic radiation-induced xerostomia following treatment for head and neck cancer. J Clin Oncol. 2012;30(suppl; abstr 5527).

117.

Simcock R, Fallowfield L, Monson K, et al. ARIX: a randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer. Ann Oncol. 2013;24(3):776–83.PubMed

118.

Stankovic P, Stankovic M, Petrovic D, et al. Functional outcome and survival rate for oral and oropharyngeal carcinoma. Clin Otolaryngol. 2012;37:22–3.

119.

Steenbakkers RJHM, Beetz I, Chouvalova O, et al. Quantec dose volume constraints for parotid glands are feasible only in a minority of H&N patients treated with IMRT. Radiother Oncol. 2012;103:S202–3.

120.

Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27(11):1864–71.PubMed

121.

Tam M, Riaz N, Schupak K, et al. Sparing bilateral ib and contralateral high level ii nodes in node-positive (N+) oropharyngeal carcinoma (OPC) improves quality of life on a prospective self-reported xerostomia questionnaire. Int J Radiat Oncol Biol Phys. 2013;87(2):S437–8. (Abstract No. 2613).

122.

Tam M, Riaz N, Schupak K, et al. Sparing low-risk nodes in node-positive (N+) oropharyngeal carcinoma (OPC) improves dysphagia outcomes and chronic peg rates. Int J Radiat Oncol Biol Phys. 2013;87(2):S437. (Abstract No. 2612).

123.

Thompson TL, Pagedar NA, Karnell LH, et al. Factors associated with mortality in 2-year survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg. 2011;137(11):1100–5.PubMed

124.

Tribius S, Prosch C, Raguse M, et al. Dry mouth and sticky saliva-quality of life domains most affected in the acute toxicity phase of radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84(3):S645–6.

125.

Urba S, Gatz J, Shen W, et al. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy. Oral Oncol. 2012;48(8):723–9.PubMed

126.

van den Brink JL, Moorman PW, de Boer MF, et al. Impact on quality of life of a telemedicine system supporting head and neck cancer patients: a controlled trial during the postoperative period at home. J Am Med Inform Assoc. 2007;14(2):198–205.PubMedCentralPubMed

127.

van der Meulen IC, May AM, de Leeuw JR, et al. Long-term effect of a nurse-led psychosocial intervention on health-related quality of life in patients with head and neck cancer: a randomised controlled trial. Br J Cancer. 2014;110(3):593–601.

128.

van Herpen CM, Mauer ME, Mesia R, et al. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer. 2010;103(8):1173–81.PubMedCentralPubMed

129.

Vargo J, Heron D, Ferris R, et al. Prospective evaluation of patient-reported quality-of-life outcomes following SBRT (plus or minus) cetuximab for locally-recurrent, previously-irradiated head-and-neck cancer. Am J Clin Oncol. 2012;35(2):187–8.

130.

Vargo JA, Heron DE, Ferris RL, et al. Prospective evaluation of patient-reported quality-of-life outcomes following SBRT +/− cetuximab for locally-recurrent, previously-irradiated head and neck cancer. Radiother Oncol. 2012;104(1):91–5.PubMed

131.

Vergeer MR, Doornaert PA, Rietveld DH, et al. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys. 2009;74(1):1–8.PubMed

132.

Vilela LD, Nicolau B, Mahmud S, et al. Comparison of psychosocial outcomes in head and neck cancer patients receiving a coping strategies intervention and control subjects receiving no intervention. J Otolaryngol. 2006;35(2):88–96.PubMed

133.

Wilson JA, Carding PN, Patterson JM. Dysphagia after nonsurgical head and neck cancer treatment: patients’ perspectives. Otolaryngol Head Neck Surg. 2011;145(5):767–71.PubMed

134.

Woolley E, Magennis P, Shokar P, et al. The correlation between indices of deprivation and health-related quality of life in patients with oral and oropharyngeal squamous cell carcinoma. Br J Oral Maxillofac Surg. 2006;44(3):177–86.PubMed

135.

Yang H, Hu W, Wang W, et al. Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2013;85(1):e47–54.PubMed

136.

Zuydam AC, Lowe D, Brown JS, et al. Predictors of speech and swallowing function following primary surgery for oral and oropharyngeal cancer. Clin Otolaryngol. 2005;30(5):428–37.PubMed

137.

Singer S, Arraras JI, Chie WC, et al. Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological review. Qual Life Res. 2013;22(8):1927–41.PubMed

138.

Bottomley A, Flechtner H, Efficace F, et al. Health related quality of life outcomes in cancer clinical trials. Eur J Cancer. 2005;41(12):1697–709.PubMed

139.

Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44.PubMed

140.

Romesser PB, Tam MM, Zhang Z, et al. Prospective dysphagia quality of life scores and treatment outcomes in oropharyngeal cancer patients: is it time to reconsider the prophylactic percutaneous endoscopic gastrostomy? Int J Radiat Oncol Biol Phys. 2013;87(2):S131.

141.

Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(9 Suppl):2026–46.PubMed

142.

Langendijk H, Bijl HP, Steenbakkers R, et al. The importance of geriatric assessment using the nullfrailty indexnull among patients with head and neck cancer treated with radiotherapy: toxicity and quality of life. Eur J Cancer. 2011;47:S86.

143.

Fisher J, Scott C, Scarantino CW, et al. Phase III quality-of-life study results: impact on patients’ quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer—RTOG 97-09. Int J Radiat Oncol Biol Phys. 2003;56(3):832–6.PubMed

144.

Klein J, Livergant J, Ringash J. Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review. Oral Oncol. 2014;50(4):254–62.PubMed

145.

Gourin CG, Kaboli KC, Boyce BJ, et al. Factors associated with nonparticipation in one-year quality-of-life assessment in patients with head and neck squamous cell carcinoma. Laryngoscope. 2010;120(7):1435–43.PubMed

146.

Meirovitz A, Murdoch-Kinch CA, Schipper M, et al. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66(2):445–53.PubMed

147.

Handschel J, Naujoks C, Kubler NR, et al. Fear of recurrence significantly influences quality of life in oral cancer patients. Oral Oncol. 2012;48(12):1276–80.PubMed

Titel: The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review
verfasst von: Erika Wissinger
Ingolf Griebsch
Juliane Lungershausen
Michael Byrnes
Karin Travers
Chris L. Pashos
Publikationsdatum: 01.12.2014
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 12/2014
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-014-0199-x

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials

Objectivity and Equity: Clarity Required. A Response to Hill and Olson

Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”

Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”

A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions

A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments